Nishadi lepa and Gudaharitaki in Hemorrhoids

Clinical evaluation of the effect of Nishadi lepa and Gudaharitaki in the management of Arsha w.s.r. Hemorrhoids - NIL

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/04/109138

Enrollment

Registered

2026-04-23

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K640- First degree hemorrhoids Health Condition 2: K641- Second degree hemorrhoids

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patient aged between 20-60 years 2) Irrespective of sex 3) 1st and 2nd degree Arsha 4) Patient of any caste, religion, & occupation 5) Patient who unwilling for surgery

Exclusion criteria

Exclusion criteria: 1) Patients below 20 and more than 60 years age 2) 3rd and 4th degree pile mass 3) Rectal prolapse 4) Carcinoma of rectum 5) Pregnancy Lactating women. Patients with other systemic disorders like diabetes mellitus, malignancy, chronic renal failure etc.

Design outcomes

Primary

Measure	Time frame
Assessment will be based on clinical observations made before, during, and after the treatment. Key parameters include the presence and severity of constipation, which may contribute to disease progression. Itching at the anal verge will be noted as an indicator of irritation or inflammation. Pain intensity and its variation during and after treatment will also be evaluated. Bleeding per rectum (P/R), including frequency and amount, will be carefully observed. Additionally, the number of pile masses will be recorded, along with their size, to assess the extent of the condition and monitor therapeutic response effectively over time.Timepoint: 60 days	—

Measure

Time frame

Assessment will be based on clinical observations made before, during, and after the treatment. Key parameters include the presence and severity of constipation, which may contribute to disease progression. Itching at the anal verge will be noted as an indicator of irritation or inflammation. Pain intensity and its variation during and after treatment will also be evaluated. Bleeding per rectum (P/R), including frequency and amount, will be carefully observed. Additionally, the number of pile masses will be recorded, along with their size, to assess the extent of the condition and monitor therapeutic response effectively over time.Timepoint: 60 days

—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Deepali Sundari verma

Government Ayurvedic College and Hospital

drdeepali261996@gmail.com9430471341

Outcome results